Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey
- PMID: 37183192
- PMCID: PMC10183304
- DOI: 10.1007/s13555-023-00929-9
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey
Abstract
Introduction: The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey study was conducted globally in 2020 to understand how disease perceptions, including disease severity, treatment goals, and quality of life (QoL), have evolved recently, especially for mild-to-moderate psoriatic disease. Here, key findings from the UPLIFT survey based on respondents located in the US are presented. Leveraging results from the UPLIFT survey could lead to more effective interactions between patients and physicians and greater patient satisfaction.
Methods: UPLIFT was a multinational web-based survey of dermatologists, rheumatologists, and patients who self-reported a healthcare provider diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) conducted from March 2, 2020, to June 3, 2020.
Results: US respondents included 1006 patients (26.4% of global population; PsO only, n = 535; PsA only, n = 72; PsO and PsA, n = 399) and 216 physicians (dermatologists, n = 115; rheumatologists, n = 101). Most patients (66.4%) reported a body surface area (BSA; assessed by number of palms) of ≤ 3; of these, 56.2% rated their disease as moderate or severe. Most patients with PsO felt they were somewhat (40.1%) or very (49.3%) closely aligned with their dermatologists regarding treatment goals. Alternately, most patients with PsA felt that they were not too closely (32.1%) or not at all (59.3%) aligned with their rheumatologists. Most patients reported either a moderate (PsO, 35.5%; PsA, 31.8%) or strong (PsO, 47.7%; PsA, 53.9%) need for better treatments. Across BSA subgroups, most patients (60.8% to 86.1%) had a Dermatology Life Quality Index score ≥ 6, indicating at least a moderately impacted QoL.
Conclusions: Despite more treatment options, management of psoriatic disease remains suboptimal, with many patients reporting moderate-to-severe disease and impaired QoL, even with limited skin involvement. Results further suggest an unmet need for alignment between patients and physicians in the US to optimize the management of PsO and PsA.
Keywords: Disease burden; Health survey; Patient satisfaction; Psoriasis; Psoriatic arthritis; Quality of life; Special area; Symptom; Treatment goals; United States.
Plain language summary
The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was an online survey conducted in 2020. The participants were patients who self-reported a healthcare provider diagnosis of psoriasis and/or psoriatic arthritis, dermatologists, and rheumatologists. The survey was distributed in several countries in North America, Europe, and Japan and a total of 3806 patients responded to the survey. Results from US patients and physicians are presented here.UPLIFT was designed to understand current perceptions of patients and physicians relating to psoriasis and psoriatic arthritis, especially for mild-to-moderate disease. Participants were surveyed regarding treatments, severity of disease, impact on quality of life, treatment goals, and patient-physician interactions.In the US, 1006 patients and 216 physicians completed the survey and were included in the analysis. Most patients had limited skin involvement but still rated their disease as moderate or severe. Regardless of whether patients had a small or large amount of skin involved, most reported at least a moderately impacted quality of life. The survey results suggested that there was disconnect between patients and physicians regarding treatment goals, treatment satisfaction, disease severity, and their recollection of what occurred during physician office visits. Despite new treatment options in recent years, the UPLIFT survey results show that US patients with psoriasis and psoriatic arthritis still experience a great disease burden and could benefit from better communication with physicians to optimize their treatment.
© 2023. The Author(s).
Conflict of interest statement
Joseph F. Merola: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, and UCB—consultant and/or investigator. Alexis Ogdie: AbbVie, Amgen Inc., Novartis, and Pfizer—grant/research support; AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, CorEvitas’ Psoriatic Arthritis/Spondyloarthritis Registry (formerly Corrona), Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB—consultant; royalties to husband from Novartis. Alice B. Gottlieb: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project)—honoraria as an advisory board member, non-promotional speaker or consultant; AnaptysBio, Janssen, Moonlake Therapeutics AG, Novartis, Ortho Dermatologics, Sun Pharma, Bristol Myers Squibb, and UCB Pharma—research/educational grants; all funds go to the Icahn School of Medicine at Mount Sinai. Linda Stein Gold: AbbVie, Amgen, Arcutis, Celgene Corporation, Dermira, Dermavant, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB, and Valeant—honoraria, grants, and/or research funding as a speaker, investigator, and/or advisory board member. Andrea Flower, Shauna Jardon, and Yuri Klyachkin: Amgen Inc.—employees and stockholders. Mark Lebwohl: Mount Sinai—employment; AbbVie, Amgen Inc., Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB—research funds; Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica—consultant.
Figures





Similar articles
-
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.Dermatol Ther (Heidelb). 2022 Jan;12(1):61-78. doi: 10.1007/s13555-021-00635-4. Epub 2021 Oct 25. Dermatol Ther (Heidelb). 2022. PMID: 34704231 Free PMC article.
-
Patient perceptions of psoriatic disease in Japan: Results from the Japanese subgroup of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey.J Dermatol. 2022 Sep;49(9):818-828. doi: 10.1111/1346-8138.16423. Epub 2022 May 27. J Dermatol. 2022. PMID: 35624553 Free PMC article.
-
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10. doi: 10.1111/jdv.13150. Epub 2015 Apr 16. J Eur Acad Dermatol Venereol. 2015. PMID: 25885420 Free PMC article.
-
A Joint Consensus of Rheumatologists and Dermatologists on Early Detection and Effective Management of Psoriatic Arthritis: India's Perspective.Indian J Dermatol. 2022 Jul-Aug;67(4):479. doi: 10.4103/ijd.ijd_939_20. Indian J Dermatol. 2022. PMID: 36578740 Free PMC article. Review.
-
Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists.Clin Rheumatol. 2022 May;41(5):1271-1283. doi: 10.1007/s10067-022-06077-3. Epub 2022 Jan 26. Clin Rheumatol. 2022. PMID: 35083564 Free PMC article. Review.
Cited by
-
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.Dermatol Ther (Heidelb). 2024 Oct;14(10):2805-2825. doi: 10.1007/s13555-024-01258-1. Epub 2024 Sep 16. Dermatol Ther (Heidelb). 2024. PMID: 39283415 Free PMC article.
-
Patient-Reported and Economic Racial and Ethnic Disparities in Patients with Psoriatic Arthritis: Results from the National Health and Wellness Survey.Rheumatol Ther. 2024 Dec;11(6):1569-1590. doi: 10.1007/s40744-024-00717-7. Epub 2024 Sep 29. Rheumatol Ther. 2024. PMID: 39343841 Free PMC article.
-
Perspectives of Japanese patients on psoriatic disease burden: Results from "Psoriasis and Beyond," the Global Psoriatic Disease Survey.J Dermatol. 2024 Oct;51(10):1298-1309. doi: 10.1111/1346-8138.17424. Epub 2024 Sep 10. J Dermatol. 2024. PMID: 39254310 Free PMC article.
-
The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy.Psoriasis (Auckl). 2024 Nov 28;14:167-174. doi: 10.2147/PTT.S478352. eCollection 2024. Psoriasis (Auckl). 2024. PMID: 39624651 Free PMC article.
-
Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry.Dermatol Ther (Heidelb). 2025 Aug;15(8):2117-2130. doi: 10.1007/s13555-025-01456-5. Epub 2025 Jun 11. Dermatol Ther (Heidelb). 2025. PMID: 40498388 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous